Our technology in action
Heat-activated liposomal technology in action
View Video
- Liposomes containing a chemotherapy agent circulate in solution throughout the bloodstream and pass into tumors through leaks in the vasculature
- Upon application of focused heat, vasculature leakage increases and the unique heat-sensitive liposome membrane dissipates, releasing chemotherapeutic drug directly into the tumor
- After drug is released into the tumor, the tumor shrinks and dies
The science of LTSL has already been reviewed and validated by major scientific institutions and investigators. The technology, further developed by Celsion, is being used to enhance existing chemotherapeutics.
The graphs below represent studies that were conducted that demonstrate ThermoDox's comparative value in delivering high concentrations of doxorubicin at clinically achievable temperatures, 39-43ºC. In vitro experiments represented in the graph below, demonstrate the rapid release of doxorubicin from ThermoDox when activated at temperatures above 39.5ºC. For comparison, the non-heat sensitive liposomal formulation shows little increase in release characteristics at similar temperatures.
(Doxil is a registered trademark of Johnson and Johnson)
In vivo experiments represented in the graph below, show drug concentration in tumors at temperatures above 39.5ºC to be substantially greater with the ThermoDox formulation when compared to either free doxorubicin or a non-temperature sensitive liposomal formulation administered to mice with tumor xenografts.
http://www.celsion.com/techInAction.cfm